Elan Pharmaceuticals. Elan Pharmaceuticals, a U.S-based multinational pharmaceutical company, is evaluating an export sale of its cholesterol-reduction drug with a prospective Indonesian distributor. The purchase would be for 1,650 million Indonesian rupiah (Rp), which at the current spot exchange rate of Rp9,450/S, translates into $174,603.17. Although not a big sale by company standards, company policy dictates that sales must be settled for P at least a minimum gross margin, in this case, a cash settlement of $168,000. The current 90-day forward rate is Rp9.950/5. Although this rate appeared unattractive, Elan had to contact several major banks before even finding a in forward quote on the rupiah. The consensus of currency forecasters at the moment, however, is that the rupiah will continue to strengthen, possibly rising to Rp10,200/S over the coming 90 to 120 days. Analyze the prospective sale and make a hedging recommendation. ns How much in US dollars will Elan receive in 90 days without a hedge if the expected spot rate in 90 days is assumed to be Rp9.450/5? S(Round to the nearest cent)